Result of AGM

Stem Cell Sciences plc
30 May 2006


Immediate Release                                                  30th May 2006


                             Stem Cell Sciences PLC

                                 RESULT OF AGM

At the Annual General Meeting held on 30.5.06 all the resolutions contained
within the Notice of Meeting were passed.

Two copies of the resolutions passed as special business at the AGM have been
submitted to the UK Listing Authority and will shortly be available for
inspection at the UK Listing Authority's Document Viewing Facility, which is
situated at Financial Services Authority, 25 The North Colonnade, Canary Wharf,
London, E14 5HS.

                                     -ENDS-

For further information please contact:

Stem Cell Sciences plc                                           0131 662 9829
Peter Mountford

Weber Shandwick | Square Mile                                    020 7067 2587
James White

Notes to Editors:

Notes to Editors

Stem Cell Sciences plc (SCS) is a global biotechnology company focused on the
development of stem cell technologies. The Company has established a leading
intellectual property (IP) and technology portfolio that enables the commercial
application of stem cells in pharmaceutical and biotechnology drug discovery,
providing the Company with an early-stage revenue stream. In the longer term,
the Company is developing regenerative, cell-based therapies.

Stem Cell Sciences has four business units focused on key sustainable business
strategies.

SC Proven provides serum free, cell culture media (liquid formulations) and
reagents that enable the growth and differentiation of stem cells for basic
research and drug discovery purposes. The first commercially available product,
a mouse embryonic stem cell growth medium, has been exclusively licensed for
manufacture and marketing to Chemicon, a division of Serologicals Inc.
SC Licensing licenses SCS proprietary technologies, such as Internal Ribosome
Entry Site (IRES) and Stem Cell Selection, for application in laboratory-based
research and discovery. Current licenses for IRES are in place with Deltagen Inc
and Lexicon Genetics Inc.

SC Services will provide specialised stem cell production for basic research and
drug discovery, including high-throughput applications.
SC Therapies goal is to develop safe and effective cell-based therapies for
currently incurable diseases. The first programme is being undertaken by SCS'
Japanese affiliate, which recently announced the exclusive licensing of human
multipotent tissue stem cells (hMADS) for therapeutic purposes. SCS KK plans to
conduct initial preclinical studies to evaluate their potential application in
the treatment of Duchene's Muscular Dystrophy.

SCS plc is a global Company with operations in the UK, Australia, and via its
associate company in Japan. Each company is affiliated with a regional centre of
academic excellence facilitating the global commercialisation of new IP and cell
lines. These include the Institute of Stem Cell Research (ISCR), Edinburgh, UK,
RIKEN Centre for Development Biology, Kobe, Japan and the Australian Stem Cell
Centre, Melbourne, Australia.

SCS, which listed on the London Alternative Investment Market in July 2005, was
founded in 1994 to commercialise findings from the ISCR and Monash University,
Melbourne, Australia. The Company is a participant in two research projects
under the European Union's Framework Six Programme for Research and Technology
Development and is a contributor to the UK Stem Cell Initiative.


                      This information is provided by RNS
            The company news service from the London Stock Exchange